How to buy Abiomed stock

Abiomed, Inc is a medical devices business based in the US. Abiomed shares (ABMD) are listed on the NASDAQ and all prices are listed in US Dollars.

Abiomed share price

Use our graph to track the performance of ABMD stocks over time.

Abiomed shares at a glance

• Key figures

Information last updated 2021-05-08.

52-week range	$180.29 - $355.94
50-day moving average	$320.64
200-day moving average	$305.50
Wall St. target price	$374.00
PE ratio	60.083
Dividend yield	N/A (0%)
Earnings per share (TTM)	$4.94

Buy Abiomed shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Abiomed stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Abiomed, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Abiomed under- or over-valued?

Valuing Abiomed stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abiomed's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Abiomed's P/E ratio

Abiomed's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 60x. In other words, Abiomed shares trade at around 60x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Abiomed's PEG ratio

Abiomed's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.75. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Abiomed's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Abiomed's EBITDA

Abiomed's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $252.2 million.

The EBITDA is a measure of a Abiomed's overall financial performance and is widely used to measure a its profitability.

Abiomed financials

Revenue TTM	$847.5 million
Operating margin TTM	27.09%
Gross profit TTM	$685.6 million
Return on assets TTM	10.59%
Return on equity TTM	18.83%
Profit margin	26.61%
Book value	$29.37
Market capitalisation	$13.4 billion

TTM: trailing 12 months

Shorting Abiomed shares

There are currently 1.0 million Abiomed shares held short by investors – that's known as Abiomed's "short interest". This figure is 14.9% down from 1.2 million last month.

There are a few different ways that this level of interest in shorting Abiomed shares can be evaluated.

Abiomed's "short interest ratio" (SIR)

Abiomed's "short interest ratio" (SIR) is the quantity of Abiomed shares currently shorted divided by the average quantity of Abiomed shares traded daily (recently around 265098.15789474). Abiomed's SIR currently stands at 3.8. In other words for every 100,000 Abiomed shares traded daily on the market, roughly 3800 shares are currently held short.

However Abiomed's short interest can also be evaluated against the total number of Abiomed shares, or, against the total number of tradable Abiomed shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Abiomed's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Abiomed shares in existence, roughly 20 shares are currently held short) or 0.0255% of the tradable shares (for every 100,000 tradable Abiomed shares, roughly 26 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Abiomed.

Find out more about how you can short Abiomed stock.

Abiomed share dividends

We're not expecting Abiomed to pay a dividend over the next 12 months.

Have Abiomed's shares ever split?

Abiomed's shares were split on a 2:1 basis on 1 October 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Abiomed shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Abiomed shares which in turn could have impacted Abiomed's share price.

Abiomed share price volatility

Over the last 12 months, Abiomed's shares have ranged in value from as little as $180.29 up to $355.94. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Abiomed's is 1.2834. This would suggest that Abiomed's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Abiomed overview

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2. 5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5. 0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; and Impella Connect, a cloud-based technology that enables secure, cloud-based, and remote viewing of the Automated Impella Controller for physicians and hospital staffs.

Frequently asked questions

• What percentage of Abiomed is owned by insiders or institutions?

  Currently 2.124% of Abiomed shares are held by insiders and 97.851% by institutions.

• When does the fiscal year end for Abiomed?

  Abiomed's fiscal year ends in March.

• Where is Abiomed based?

  Abiomed's address is: 22 Cherry Hill Drive, Danvers, MA, United States, 01923

• What is Abiomed's ISIN number?

  Abiomed's international securities identification number is: US0036541003

• What is Abiomed's CUSIP number?

  Abiomed's Committee on Uniform Securities Identification Procedures number is: 003654100